Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
PAVmed to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
-
PAVmed Closes $13.4 Million Common Stock Registered Direct Offering Priced At-the-Market under Nasdaq Rules
-
PAVmed (PAVM) Announces Registered Direct Offering of its Common Stock
-
PAVmed Announces Registered Direct Offering of its Common Stock Priced At-the-Market under Nasdaq Rules
-
PAVmed Closes Additional $8.1 Million Common Stock Registered Direct Offering
-
PAVmed (PAVM) Prices Additional $8.1 Million Common Stock Registered Direct Offering
-
PAVmed Announces Pricing of Additional $8.1 Million Common Stock Registered Direct Offering
-
PAVmed (PAVM) Announces 5.6M Share Registered Direct Offering of its Common Stock Priced at $1.60/sh
-
PAVmed Announces Registered Direct Offering of its Common Stock
-
PAVmed to Present at Maxim Group’s COVID-19 Webinar on July 16, 2020
-
PAVmed Receives $6.3 Million in Gross Proceeds from Completion of November 2019 Financing
-
PAVmed Secures Financing up to $14 Million for Advancement of its Lead Products to Commercialization
-
PAVmed (PAVM) Announces $1.6M Registered Direct Offering of its Common Stock
-
PAVmed Announces Registered Direct Offering of its Common Stock
-
Dawson James Securities Announces the Closing of Oversubscribed $10,350,000 Rights Offering for PAVmed, Inc.
-
Dawson James Securities Announces the Closing of Oversubscribed $10,350,000 Rights Offering for PAVmed, Inc.
-
PAVmed Closes Oversubscribed Rights Offering for Gross Proceeds of $10,350,000
-
PAVmed to Receive $10.4 Million in Gross Proceeds from Oversubscribed Rights Offering
-
PAVmed Sets Record Date for Previously Announced Rights Offering

